NCT06767254 A Machine Learning Approach to Connect Multiple Myeloma Complexity to Early Disease Recurrence
| NCT ID | NCT06767254 |
| Status | Recruiting |
| Phase | — |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna |
| Condition | Multiple Myeloma (MM) |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2024-10-30 |
| Primary Completion | 2026-04-02 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2024-10-30 with a primary completion date of 2026-04-02.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a non-interventional, national, multicenter prospective non-profit observational study aiming at improving the accuracy of risk prediction in multiple myeloma (MM) by applying machine-learning tools for data processing to develop model(s) predicting response to therapy and the probability of early relapse for MM patients.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * Signed Informed Consent form for study participation and personal data processing * Diagnosis of active multiple myeloma Exclusion Criteria: * None
Contact & Investigator
Elena Zamagni, MD, PhD
PRINCIPAL INVESTIGATOR
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Frequently Asked Questions
Who can join the NCT06767254 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Multiple Myeloma (MM). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06767254 currently recruiting?
Yes, NCT06767254 is actively recruiting participants. Contact the research team at e.zamagni@unibo.it for enrollment information.
Where is the NCT06767254 trial being conducted?
This trial is being conducted at Meldola, Italy, Bologna, Italy, Cagliari, Italy, Naples, Italy.
Who is sponsoring the NCT06767254 clinical trial?
NCT06767254 is sponsored by IRCCS Azienda Ospedaliero-Universitaria di Bologna. The principal investigator is Elena Zamagni, MD, PhD at IRCCS Azienda Ospedaliero-Universitaria di Bologna. The trial plans to enroll 200 participants.